Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + 5-fluorouracil
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of paclitaxel, cisplatin, and 5-fluorouracil. This regimen has shown significant activity in treating locally advanced squamous cell carcinoma of the head and neck (SCCHN) and advanced gastric carcinoma. It works through multiple mechanisms including microtubule stabilization, DNA damage, and thymidylate synthase inhibition.
- Brand names
- Adrucil
- Other names
- PPF
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + cisplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + 5-fluorouracil.